dTAGV-1 TFA

产品编号 T40251Cas号 2624313-15-9

dTAGV-1 TFA is a highly effective and specific compound that targets mutant FKBP12 F36V fusion proteins for degradation. It possesses potent activity in inducing the degradation of the FKBP12 F36V -Nluc protein in living organisms.

dTAGV-1 TFA

产品编号 T40251Cas号 2624313-15-9

规格	价格	库存	数量
5 mg	¥ 8,990	35日内发货

大包装 & 定制

加入购物车

实验操作小课堂

联系我们获取更多批次信息

资源下载

产品操作手册

TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

产品介绍

生物活性

产品描述	dTAGV-1 TFA is a highly effective and specific compound that targets mutant FKBP12 F36V fusion proteins for degradation. It possesses potent activity in inducing the degradation of the FKBP12 F36V -Nluc protein in living organisms.
体外活性	dTAGV-1 (0.1 nM-10 μM; 24 h) TFA induces potent degradation of FKBP12 F36V -Nluc with no effects on FKBP12 WT -Nluc in 293FT cells[1]. dTAGV-1 (125-2000 nM; 24 h) TFA co-treatment with THAL-SNS-032 leads to pronounced degradation of both LACZ-FKBP12 F36V and CDK9[1]. dTAGV-1 (500 nM; 1-24 h) TFA leads to rapid KRAS G12V and pERK1/2 degradation[1]. dTAGV-1 (50-5000 nM; 24 h) TFA enables EWS/FLI degradation in Ewing sarcoma[1].
体内活性	dTAGV-1 (35 mg/kg; i.p. once daily for 4 days) TFA induces degradation of FKBP12 F36V -Nluc in mice[1]. dTAGV-1 (2-10 mg/kg; i.p.) TFA exhbits half-lives (T 1/2 =3.64 and 4.4 h), C max (595 and 2123 ng/mL) and great exposure (AUC inf =3136 and?18517 h?ng/mL) in mice[1]. dTAGV-1 (2 mg/kg; i.v.) TFA exhbits half-life (T 1/2 =3.02 h), C max (7780 ng/mL) and great exposure (AUC inf =3329 h?ng/mL) in mice[1]. Animal Model: 8-week-old immunocompromised female mice were transplanted with MV4;11 luc-FKBP12 F36V cells[1]Dosage: 35 mg/kg Administration: I.p. once daily for 4 days Result: Observed striking loss of bioluminescent signal 4?h after the first and three administrations. Degradation evident 28?h after the final administration.